Yaostone Technology: The Company has not recently received any notifications or plans from controlling shareholders regarding share reduction.

Securities Star News: YaoShi Technology (300725) responded to investor questions on the Investor Relations platform on March 23.

Investor: Is the information reported by Economic Observer from March 5-7 about “the controlling shareholder reducing holdings by no more than 4.99 million shares” true?

YaoShi Technology Secretary: Dear investor, hello! The company has not recently received any notices or plans from the controlling shareholder regarding share reduction. All major company information is officially disclosed through China Securities Regulatory Commission designated media, Juchao Information. Please refer to the announcements published by the company on the official channels mentioned above. Thank you!

Investor: Hello, Secretary. Given the company’s stock price has been depressed for a long time, falling from a high of 200 yuan to the current 37 yuan, many shareholders are suffering significant losses. Based on long-term observation of the CRO sector and considering the company’s business situation, I have communicated with the secretaries of companies like Boteng, Ruizhi, Boji, and Kanglong, and suggested that their management teams coordinate more with you to acquire YaoShi through share issuance or cash, to strengthen their core businesses and truly benefit the public with innovative drug R&D. I hope you consider this.

YaoShi Technology Secretary: Dear investor, hello! The company’s management team remains confident in the company’s development prospects and intrinsic value. They focus on continuous technological innovation, deepening customer cooperation, and improving operational efficiency to steadily strengthen the company’s core competitiveness. Currently, the company’s operational team is advancing various businesses according to the established development strategy, aiming to deliver solid performance and repay investors’ trust. Regarding your suggestion to connect with other industry peers, the company currently has no undisclosed plans that should be disclosed. All major information will be announced through China Securities Regulatory Commission designated media and platforms. We understand your concerns about the stock price; stock fluctuations are influenced by many complex factors. The company believes that focusing on core businesses, continuous innovation, and achieving sustainable high-quality development are the fundamental ways to protect shareholders’ interests. Thank you!

Investor: Hello, Secretary. I noticed that the company is involved in AI pharmaceutical development and has a collaboration with Hongbo Medical on AI large models for drug development. Hongbo Medical is considered the leading AI pharmaceutical company in China. With such a low market value but huge potential, why doesn’t the company directly hold a controlling stake or acquire it?

YaoShi Technology Secretary: Dear investor, hello! The company currently has no cooperation with Hongbo Medical in AI pharmaceuticals. The company’s development is always based on its own strategic and core capabilities, focusing on technological innovation and service upgrades to promote sustainable growth of its main business. The Interactive Easy platform is not a formal disclosure channel; all information that should be disclosed is published on Juchao Information. Please be aware of risks and invest rationally. Thank you!

The above content is compiled from public information by Securities Star, generated by AI algorithms (Network Information Backup 310104345710301240019), and does not constitute investment advice.